Report of Foreign Issuer (6-k)
April 27 2020 - 8:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of April 2020 (No. 4)
Commission
File Number 001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation
of registrant’s name into English)
23
Hata’as Street
Kfar
Saba, Israel 44425
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
The
press release attached hereto as Exhibit 99.1 entitled “Cellect Biotechnology Continues to Achieve Milestones; Receives
New Patent Allowance in Canada” is hereby incorporated by reference into the Registrant’s Registration Statements
on Form S-8 (Registration Nos. 333-214817, 333-220015, 333-225003 and 333-232230) and on Form F-3 (Registration No.
333-219614).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: April 27, 2020
|
CELLECT BIOTECHNOLOGY, LTD.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Eyal Leibovitz
|
|
|
Chief Financial Officer
|
2
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From May 2024 to Jun 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jun 2023 to Jun 2024